|
Volumn 8, Issue 8, 2005, Pages 648-650
|
The impact of FDA guidance on pharmacogenomic data submissions on drug development
|
Author keywords
Biomarker; Drug development; Genetic analysis; Genotyping; Pharmacogenetic assays; Pharmacogenomic analysis; Regulatory framework; Regulatory submission; Specific genetic tests
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTOCHROME P450 2C19;
CYTOCHROME P450 2C8;
CYTOCHROME P450 2C9;
CYTOCHROME P450 2D6;
DRUG;
EPIDERMAL GROWTH FACTOR RECEPTOR;
RAF PROTEIN;
RAS PROTEIN;
ARTICLE;
DNA POLYMORPHISM;
DRUG INDUSTRY;
DRUG METABOLISM;
DRUG SYNTHESIS;
FOOD AND DRUG ADMINISTRATION;
GENOME;
GENOTYPE PHENOTYPE CORRELATION;
HUMAN;
IN VITRO STUDY;
PHARMACOGENOMICS;
PRACTICE GUIDELINE;
DATABASES, GENETIC;
GENE TARGETING;
GUIDELINES;
PHARMACOGENETICS;
PHARMACOLOGY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 23244435999
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (7)
|
References (7)
|